The search for treatments for neurodegenerative diseases is a major concern in light of
today's aging population and an increasing burden on individuals, families, and society …

Metformin, one of the first-line of hypoglycemic drugs, has cardioprotective, anti-
inflammatory and anticancer activities, in addition to its proven hypoglycemic effects …

Type 2 diabetes mellitus (T2DM) is a complex, chronic and progressive metabolic disease,
which is characterized by relative insulin deficiency, insulin resistance, and high glucose …

Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Metformin is a first-line drug for treating type 2 diabetes mellitus (T2DM) and one of the most
commonly prescribed drugs in the world. Besides its hypoglycemic effects, metformin also …

Parkinson's disease (PD) is a devastating neurodegenerative disorder characterized by the
progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and …

Metformin as a first-line drug for type 2 diabetes mellitus (T2DM) treatment is widely studied.
Metformin can reduce liver glucose output and improve insulin resistance. Recent evidence …

Parkinson's disease (PD) is a common neurodegenerative disease developed due to the
degeneration of dopaminergic neurons in the substantia nigra. There is no single effective …

Aging is a risk factor for major central nervous system (CNS) disorders. More specifically,
aging can be inked to neurodegenerative diseases (NDs) because of its deteriorating impact …

Introduction: Metformin is currently first line therapy for type 2 diabetes (T2D). The
mechanism of action of metformin involves activation of AMP-activated protein kinase …